Immune system holds clues to patients with high-risk smoldering myeloma likely to benefit from treatment

For many patients with a condition that often precedes multiple myeloma, early treatment can slow or delay the progression to myeloma. In a new study, investigators at Dana-Farber Cancer Institute demonstrate that changes in immune system cells can indicate which patients with high-risk “smoldering” myeloma are likely to progress to myeloma and which will benefit the most from treatment.